Johnson & Johnson/Novartis (Fentanyl) (COMP/39.685) [Archived]
Johnson & Johnson/Novartis (Fentanyl) (COMP/39.685) [Archived]

The following Competition practice note provides comprehensive and up to date legal information covering:

  • Johnson & Johnson/Novartis (Fentanyl) (COMP/39.685) [Archived]
  • Case facts
  • Timeline
  • Commentary
  • Related cases


ARCHIVED–this archived case hub reflects the position at the date of the decision of 10 December 2013; it is no longer maintained.

See further, timeline, commentary and related cases.

Case facts

OutlineEuropean Commission Article 101 TFEU investigation into Johnson & Johnson and Novartis (Fentanyl) (case number COMP/39.685).

Latest developmentsThe Commission has imposed fines of €10.798m on Johnson & Johnson (and subsidiaries) and €5.493m on Novartis (and subsidiaries).

Parties• Johnson & Johnson (and subsidiaries)
• Novartis (and subsidiaries)

Market(s)Pharmaceuticals (painkiller medicines).

The drug involved is Fentanyl, a painkiller 100 times stronger than morphine.

Popular documents